Exagen Inc
Exagen Inc. is a U.S.-based medical technology company focused on autoimmune and rheumatic disease testing. It develops and commercializes the AVISE® portfolio, which helps physicians differentiate, diagnose, prognose, and monitor complex conditions such as connective tissue diseases, SLE, and RA.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueFlagship testing used to differentiate connective tissue diseases and related autoimmune conditions.
New biomarker content added to improve diagnostic accuracy and support broader clinical use.
Tests used to follow disease activity and support treatment decisions over time.
Customers
Exagen sells primarily to rheumatologists and other physicians treating patients with overlapping autoimmune symptoms. It also serves primary care physicians, specialists, and healthcare providers that need more specific testing than traditional biomarker panels can offer. The business depends on physician adoption, payer reimbursement, and repeat utilization in a concentrated specialty market.
Primary users of AVISE® tests for differential diagnosis and monitoring of CTD, SLE, and RA.
Order or refer patients with unclear autoimmune symptoms to support earlier specialist decision-making.
Use testing to improve diagnostic clarity in multispecialty or in-house laboratory settings.
Influence net revenue through coverage, denial rates, and collection outcomes.
Strategy
Exagen's strategy is to expand adoption of AVISE® testing by improving biomarker content, sales reach, and customer service. Management is also focused on measured territory expansion where physician demand and near-term profitable growth are most likely, while preserving cash and access to capital.
New biomarkers are driving higher average selling prices and test utilization.
More territories can increase physician access without overextending resources.
Specialty diagnostics depend on physician trust, turnaround, and support.
The company may need external capital before operating cash flow is sufficient.
Geography
Exagen is operationally concentrated in the United States, where it runs its field sales organization and serves most of its physician customers. The company also relies on some non-U.S. suppliers, including Germany, for reagents and other materials used in testing, which creates import and tariff exposure. Its principal executive offices are in Vista, California, and its warehouse/laboratory operations are central to service continuity.
Risks
Exagen faces execution risk from its reliance on a narrow autoimmune testing market, payer reimbursement variability, and continued operating losses. It also has meaningful supply-chain and financing risk because critical reagents come from sole-source suppliers and the company may need external capital to fund operations. Competitive pressure from large commercial labs and traditional diagnostic methods could limit adoption if Exagen cannot sustain clinical differentiation.
- Dependence on payer reimbursement and collection estimatesImpact: HighLikelihood: High
Net revenue is based on expected collections, so denial rates and policy changes can move revenue and margins.
Exposure - Sole-source supplier concentrationImpact: HighLikelihood: Medium
Critical reagents, equipment, and transport-kit components come from single suppliers, increasing disruption risk.
Exposure: Laboratory test inputs and transportation kits
- Need for additional capitalImpact: HighLikelihood: Medium
The company may not generate enough cash from operations to fund commercialization and R&D.
Exposure - Competitive pressure in autoimmune diagnosticsImpact: MediumLikelihood: Medium
Large labs and traditional biomarker testing can limit adoption and pricing power.
Exposure: Rheumatology and autoimmune-related testing market
- Trade policy and foreign sourcing exposureImpact: MediumLikelihood: Medium
Tariffs or import restrictions could raise reagent costs and compress gross margin.
Exposure
Accounting
Judgemental itemsNet revenue is estimated using historical collection experience by payor and test, so changes in assumptions affect reported sales.
Impact: Can create revenue reversals or uplift in future periods
Billing is at list price but revenue is reduced for expected denials and concessions.
Impact: Directly affects net revenue and accounts receivable
Test volume and reimbursement timing can vary by quarter, affecting revenue and margins.
Impact: Makes sequential comparisons less reliable
Interest expense, extinguishment losses, and warrant remeasurement can add volatility below operating income.
Impact: Affects net loss and financing-related line items
Similar listed companies
Publicly listed companies with a comparable business focus.
Axogen, Inc.
AXGN · Electromedical & Electrotherapeutic Apparatus
Adagene Inc.
ADAG · Pharmaceutical Preparations
Qiagen N.V
QGEN · Biological Products, (No Diagnostic Substances)
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Last updated: 24/09/2026